Skip to main content
Astria Therapeutics, Inc. logo

Astria Therapeutics, Inc. — Investor Relations & Filings

Ticker · ATXS ISIN · US04635X1028 US Manufacturing
Open in API
Filings indexed 602 across all filing types
Latest filing 2024-03-25 Regulatory Filings
Country US United States of America
Listing US ATXS

About Astria Therapeutics, Inc.

https://astriatx.com/

Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for allergic and immunologic diseases. The company's mission is to provide life-changing treatments to patients and their families. Its lead product candidate, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein being developed as a potential long-acting, preventative treatment for Hereditary Angioedema (HAE). The company has reported positive initial proof-of-concept results from its ALPHA-STAR Phase 1b/2 clinical trial for STAR-0215. Astria Therapeutics is guided by patient needs to develop differentiated therapeutics that address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events or updates about a company. The content includes clinical trial data updates, financial status, and forward-looking statements but does not contain comprehensive financial statements or detailed annual or quarterly financial reports. It is not an earnings release or a management discussion but rather an event update. The document is not a proxy, audit, or governance report. Given the nature of the Form 8-K and the content focusing on clinical trial results and company updates, the appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous filings that do not fit other categories.
2024-03-25 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-03-11 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-03-07 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 4, 2024, by Astria Therapeutics, Inc. It announces the entry into a material definitive agreement, specifically an Open Market Sale Agreement with Jefferies LLC for the potential sale of common stock. The content focuses on the terms of this financing agreement and related exhibits, including legal opinions. There are no financial statements or comprehensive financial performance data presented, nor is this an earnings release or annual/interim report. The document is a current report announcing a capital raising arrangement, which fits the category of Capital/Financing Update (CAP). The document length (6942 characters) and content confirm it is a substantive filing, not merely an announcement of a report or certification. Therefore, the appropriate classification is CAP with high confidence.
2024-03-04 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a shelf registration statement for the sale of common stock by Astria Therapeutics, Inc. It details terms of an at-the-market offering, sales agreement with Jefferies LLC, and includes risk factors, use of proceeds, dividend policy, and plan of distribution. The document is a registration and offering prospectus supplement, which is a capital raising document. It is not a financial report, earnings release, management discussion, or any other report type. It is clearly a capital/financing update related to a stock offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, not just an announcement or a brief note, so it is not an RPA or RNS. Confidence is high given the clear nature of the document as a prospectus supplement for a stock offering.
2024-03-04 English
10-K
Annual Report FY 2023
2024-03-04 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.